MYC is altered in 12.93% of diffuse large B-cell lymphoma patients [4].

MYC Expression is an inclusion criterion in 12 clinical trials for diffuse large B-cell lymphoma, of which 8 are open and 4 are closed. Of the trials that contain MYC Expression and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (3 open), 1 is phase 2/phase 3 (0 open), and 1 is phase 3 (1 open) [5].

MYC is altered in 4.29% of medulloblastoma patients [4].

MYC Expression is an inclusion criterion in 5 clinical trials for medulloblastoma, of which 5 are open and 0 are closed. Of the trials that contain MYC Expression and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [5].

MYC Expression is an inclusion criterion in 3 clinical trials for double-hit lymphoma, of which 1 is open and 2 are closed. Of the trials that contain MYC Expression and double-hit lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2/phase 3 (0 open) [5].

MYC is altered in 1.82% of hodgkin lymphoma patients [4].

MYC Expression is an inclusion criterion in 3 clinical trials for hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MYC Expression and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

MYC is altered in 3.39% of mantle cell lymphoma patients [4].

MYC Expression is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MYC Expression and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

MYC Expression is an inclusion criterion in 3 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 3 are open and 0 are closed. Of the trials that contain MYC Expression and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 4 (1 open) [5].

MYC is altered in 64.29% of Burkitt lymphoma patients [4].

MYC Expression is an inclusion criterion in 2 clinical trials for Burkitt lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYC Expression and Burkitt lymphoma as inclusion criteria, 2 are phase 1 (1 open) [5].

MYC is altered in 3.0% of central nervous system embryonal neoplasm patients [4].

MYC Expression is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MYC Expression and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYC Expression is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYC Expression and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYC Expression is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYC Expression and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYC Expression is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MYC Expression and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MYC is altered in 2.79% of follicular lymphoma patients [4].

MYC Expression is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYC Expression and follicular lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 42.86% of high grade B-cell lymphoma, not otherwise specified patients [4].

MYC Expression is an inclusion criterion in 2 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 1 is closed. Of the trials that contain MYC Expression and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (0 open) [5].

MYC Expression is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain MYC Expression and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [5].

MYC Expression is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain MYC Expression and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYC Expression is an inclusion criterion in 2 clinical trials for triple-hit lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYC Expression and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (0 open) [5].

MYC is altered in 2.53% of anaplastic astrocytoma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 1.86% of anaplastic oligodendroglioma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 7.91% of B-cell non-hodgkin lymphoma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 1.24% of central nervous system neoplasm patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for desmoplastic/nodular medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

MYC is altered in 1.62% of diffuse glioma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 12.98% of diffuse large B-cell lymphoma, not otherwise specified patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 1.61% of glioblastoma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for hairy cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and hairy cell leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 11.11% of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 1.09% of high-grade glioma, NOS patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for intraocular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and intraocular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 12.5% of large cell/anaplastic medulloblastoma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for large cell/anaplastic medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

MYC is altered in 5.87% of lymphoma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 1.61% of malignant glioma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and marginal zone lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 7.91% of mature B-cell non-hodgkin lymphoma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Expression and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for medulloblastoma with extensive nodularity, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 4 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 0.55% of neuroblastoma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 6.64% of non-hodgkin lymphoma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Expression and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

MYC is altered in 11.11% of primary mediastinal B-cell lymphoma patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for small intestinal lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and small intestinal lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and small lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and small lymphocytic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 4.72% of solid neoplasm patients [4].

MYC Expression is an inclusion criterion in 1 clinical trial for solid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and solid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Expression is an inclusion criterion in 1 clinical trial for transformed non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Expression and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].